Age-related macular degeneration

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Monoclonal antibody 1 substance
Phase II/III: 2 Phase III/IV: 1 Phase IV: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II/III

2 trials
  • Eyebiotech Limited Commercial
    MK-8748
    2025-524575-22-00 5 countries 2026 n=130
    Recruiting
  • Eyebiotech Limited Commercial
    MK-8748
    2025-524894-17-00 10 countries 2026 n=250
    Recruiting

Phase III/IV

1 trial
  • Consorci Mar Parc De Salut De Barcelona Academic
    BEVACIZUMAB
    2024-518990-33-00 1 country n=574
    Pending

Phase IV

1 trial
  • Medical University Of Graz Academic
    FARICIMAB
    2024-514408-15-00 1 country 2024 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Eyebiotech Limited Commercial 2 Phase II/III 2
Consorci Mar Parc De Salut De Barcelona Academic 1 Phase III/IV 0
Medical University Of Graz Academic 1 Phase IV 0
New trials by year
2024
1
2026
2
← All indication landscapes